Protokinetix Inc (PK) (PKTX) Cotización

“ At December 31, 2024, we had a $4,697 shortfall in cash and negative $3,647 in total current assets. As of December 31, 2024, we had a negative working capital equity deficit position of $127,694. Although as of the date of this Annual Report we do not believe we have sufficient capital to meet cash flow projections and carry forward our business objectives in the short-term, the Company will need additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our business.”

By their own admission PKTX is technically and in reality bankrupt.

The legal and fiduciary duty of PKTX’ directors is now to wind the company up ASAP.

Their failure to do so may be related to Mr. Smith and his French Canadian mafiosi employers’ reluctance to kill this particular cash cow.

see what happens next week. I am wondering if the results of the study are coming soon?

interesting to see volume early in the day 3/27/25. 108000

only if they didn't own any before that. If I bought at .008 and sold at .015, the stock I bought years ago at .02 or whatever gets sold for a loss.

Looks like whoever bought a boat load at 0.008 ..... sold last week at 0.015 for a nice, almost 💯, profit !!!

unfortunately, so much for that outlook

kind of a disappointing week for this stock. There was a ton of volume.

I recall thinking that was misleading, especially the headline. The stem cells restored the vision . The AAGP help the stem cells survive.

https://www.protokinetix.com/protokinetix-aagp-restores-vision-in-blind-test-subjects/

I don't recall it curing blindness in mice, but it helped the cells implanted in the eyes thrive instead of disappointing the researchers

Huge potential...already clinically tested and safe on humans...cured blindness in mice...

***PKTX..
Stem Cell Therapy Reverses Diabetes..***

According to a new study published in Science Advances, researchers have developed a novel cell transplantation technique that successfully reversed type 1 diabetes in mice, using human islets vascularized with adaptable endothelial cells for functional subcutaneous engraftment.

Breakthrough in Islet Transplantation
The innovative technique employs human reprogrammed vascular endothelial cells (R-VECs) to functionally vascularize pancreatic islets, addressing a major challenge in islet transplantation therapy1. This approach enables:

In vitro functional vascularization of islets with responsive glucose-stimulated insulin secretion

Successful reversal of hyperglycemia in diabetic mice through subcutaneous transplantation

High levels of human insulin in recipient serum, with hyperglycemia returning upon graft removal

R-VECs, engineered by transiently expressing the vascular-specific transcription factor ETV2, demonstrate remarkable adaptability by self-assembling into perfusable vascular networks and acquiring islet endothelial cell-specific characteristics when cocultured with human islets12. This breakthrough represents a significant step towards improved islet transplantation therapy, potentially offering a path to long-term insulin independence for type 1 diabetes patients34.

ncbi.nlm.nih.gov favicon
science.org favicon
pubmed.ncbi.nlm.nih.gov favicon
4 sources
Role of R-VECs in Vascularization
Microenvironmental determinants of endothelial cell ...
Reprogrammed vascular endothelial cells (R-VECs) play a crucial role in enhancing islet transplantation outcomes by providing robust vascularization. Their unique properties and adaptability make them particularly effective for supporting islet survival and function:

R-VECs form extensive vascular networks that arborize and penetrate islets, mimicking native pancreatic vasculature12

When co-cultured with islets, R-VECs acquire islet endothelial cell-specific characteristics, demonstrating remarkable adaptability34

R-VEC-formed blood vessels have larger diameters (13.5 ± 7.5 µm) compared to native human islet capillaries (6.8 ± 2.1 µm), potentially improving blood flow1

Cotransplanted R-VECs contribute substantially more to islet vascularization than host endothelial cells in subcutaneous transplants1

The vascular network formed by R-VECs successfully anastomoses with host circulation, ensuring long-term graft survival31

This advanced vascularization technique addresses a major challenge in islet transplantation, potentially improving graft survival and function while enabling transplantation in more accessible sites like the subcutaneous space.

pubmed.ncbi.nlm.nih.gov favicon
ncbi.nlm.nih.gov favicon
4 sources
Subcutaneous Transplantation Success
Subcutaneous transplantation of vascularized islets marks a significant advancement in type 1 diabetes treatment. This site offers several advantages, including a large surface area, easy accessibility for transplantation and monitoring, and potential graft retrieval if necessary1. Previous attempts at subcutaneous islet transplantation had failed due to insufficient vascularization, but the use of R-VECs overcomes this challenge by forming blood vessels that arborize and vascularize the islets, effectively connecting with the host circulation23.

Transplanted R-VECs form functional blood vessels that support islet survival

Subcutaneous site allows for non-invasive monitoring and potential graft removal

Successful reversal of hyperglycemia in diabetic mice demonstrates the technique's efficacy12

ncbi.nlm.nih.gov favicon
science.org favicon
3 sources
Implications for Type 1 Diabetes
This innovative approach addresses several key challenges in islet transplantation therapy, including the scarcity of donor organs and islet loss due to disconnection from extracellular matrix and vasculature during isolation1. By enabling effective vascularization, the technique potentially reduces inflammatory and rejection reactions that compromise islet survival1. Importantly, this method may pave the way for transplantation without the need for lifelong immunosuppression, a significant drawback of conventional approaches2. The success of this technique in animal models represents a promising step towards translating this therapy to human patients, offering hope for a more effective and durable treatment for type 1 diabetes34.

https://www.perplexity.ai/page/stem-cell-therapy-reverses-dia-clGsnmywR4ugK

This one may have potential....What is the OS?

Yeah but still very interesting to see a successful therapy using islet transplant to cure diabetes 1, which is making headlines.. And it's making headlines while it was conducted on mices, PKTX study is on human beings, much more impactful

they don't mention anything obvious specifically about AAGP or any companies. though. Could be all sorts of other research involved in islets transplantation.

Look at this guys, this is our time to shine !!!

***PKTX.. Dearest Ole Sun.. Have a Good Day and go back to sleep.. :+)

With volume like today’s so far, how could it fail?

it's got to reach .05 first : )

Company gonna get bought out ...... at $0.05 per share.

.0142 with nice bid support!

NEWS COMING!!!!!

your attitude seems to have changed

News coming!

Close at or above.015

surprised there isn't more insider buying if something is going on that's positive

see what happens next week.

News coming????
Watch for a jump in PPS

nice volume and a tiny increase in price

no movement in price, but nice volume

HyperPirate75, I see you are new to Investor's hub and to PhotoKinetix's board. Welcome to the IHub board. I look forward to your thoughts regarding PhotoKinetix's Islet transplant test.

Interesting opinion but i think you are wrong, this stock has been manipulated and accumulated for years, if they do end up posting positive data for a study about diabetes 1, the stock will go up. Islet transplant is a very new method to treat diabete 1 and Alberta uni is at the forefront of this new method, if PKTX enables safer and more efficient islet transplant, it will be a big deal

The share price will never move up. If it ever gets to five cents ..... those who bought millions and millions of shares at one cent or less will dump them all. Then the PPS will collapse again. The only true way for everyone to get something out of this stock is for there to be a negotiated total buyout. (only my opinion)

2021 was the last time this stock crossed through both the 50 and 200 day moving averages.

I am not selling. When people stop selling, it might move up

Big volume today....but as you see the PPS doesn't move....

***PKTX..If you call almost a million trades low.. :+O

Wow. Very little volume again today

***PKTX.. Whatever you say.. Ole Wise One.. :+)

I'm sorry for your loss.

shmp has just about set itself on fire. They had a fire years ago and are worth less now than after the ashes were swept up

***PKTX.. Dear "disgusted investor"...I hope your day is going well.. I have a question for you, why do you say "One thing about PKTX" on this MB, But say something totally opposite on another MB..(Natural Shrimp Inc.(SHMP).. About PKTX..???

***(Your Quote).."this stock is worse than my PKTX AAGP stock Protokinetix"..

***disgusted investor.. Don't worry about your comment on that MB(Natural Shrimp Inc.(SHMP)..At least we "Now" know what you are here on PKTX for..

***Have a great day, tell your buddy SPORT19 hello.. :+)

plenty of volume

to put around my tomato plants?

Why?

bought some more shares

I know I am not selling.

another nice day of volume 310000 2/5/25

2 more months not 3 mb

Lmao they changed the date of completion again, this time we get a precise date the 25th of march, let's see on the 25th if they put 3 more months to the clock

This thing is a dog....awful